Order in the chaos
Decks are written to persuade. The data was written to record. I work from the record.
One mind and a fleet of agents, pointed at the whole published literature — and at your question. I settle a noisy system into the few facts your decision rests on, each traced to its source, and tell you which way they point. No predictions — just the record, read until the gamble’s gone.
25
Years in biotech
$1.2B
Commercial franchise
50+
Deals evaluated
The stakes
In biotech, the fact that breaks the thesis is usually public -- and unread.
Capital moves on the pitch deck. The disqualifying detail -- a buried safety death, a missing comparator arm, the one readout an entire valuation rests on -- sits in a filing or a registry no one opened, now harder to find in a flood of machine-written output. Get it wrong, and the cost compounds at every gate.
- R&Dfund a program the science won't support
- Translationback an asset whose target product profile doesn't hold
- Clinicalmisread a readout worth millions
- Regulatoryassume a path that isn't approvable across FDA and EMA
- Commercialsize a market that isn't there
- Capitalwire on a story instead of a source
The method
Hand me the pile. I hand back the verdict.
You bring the documents and the question; I scope what you actually need, feed it through an engine that verifies every claim against the primary source, and hand back what holds -- dated before the readout, defensible line by line.
01
Scope the need
I start with the decision you are actually making -- a call, a meeting, your question in your own words -- not a generic checklist. The depth is set and named here: a fast pass over twenty thousand pages -- a data drop that lands in the middle of the night, read and back to you before the opening bell -- or a deep read over weeks.
So the read is aimed at what you need to know, and you know exactly what you are buying.
02
Hand me the pile
Your documents, your data room, your question -- in whatever shape they are in. I ingest it and wire it to the live primary record: filings, trials, patents, labels, the literature.
So your private pile and the public record sit in one view -- and the cross-domain landmine surfaces before you wire.
03
The engine verifies
Every figure is traced to its source -- verbatim line, durable id, timestamp. A model of a different lineage audits each claim and can only veto it. Every forward call is dated before the readout.
So every digit is re-checkable, the weak claim dies in private -- not in your investment committee -- and the track record is auditable, not asserted.
04
The verdict
I read every gate myself and hand back the handful of facts your decision rests on, with the logic that connects them -- in whatever form the decision needs.
So you hold a document you can carry into a committee and defend line by line.
This same provenance by construction is what the FDA's 2025 guidance on AI in regulatory work now expects -- so the output is built to a standard where ungrounded AI gets turned away.
How the engine worksWhat I can be pointed at
One engine. Every gate of the drug lifecycle.
The same discipline -- trace, break, lock -- answers the question that matters at each stage. The breadth is proven, not claimed: twenty-five years standing at every one of these gates.
The proof is on the page
Three calls where the source said what the story didn't.
STAT3 · ulcerative colitis
Abivax (ABVX)
Two Phase 3 inductions hit. A $9.3B valuation now rests on a single maintenance readout -- and the report names exactly which number to watch.
AAV gene therapy · Rett syndrome
Neurogene (NGNE)
A pediatric patient died of HLH two weeks after the high dose; the cohort was discontinued. The kind of fact a pitch deck omits and a primary-source audit does not.
gamma-secretase inhibitor · desmoid tumor
Immunome (IMNM)
Phase 3 hazard ratio 0.16; NDA filed. A clean win, read against the published record rather than the company narrative.
Who it is for
Two sides of the same table.
For capital
Know which medicines work, before you wire.
Diligence that reads an asset against the published record, not the pitch deck.
- Diligence reads -- every figure traced to the filing, trial, or paper that backs it
- Mechanism and R&D audits that test the science behind the story
- Reads on what the next data readout turns on, mapped to the published record behind it
For founders
Make a real medicine legible to capital.
Articulation that gives a sound asset the clear value case investors can underwrite.
- Grants -- SBIR and beyond, written fast and managed from draft to award
- Target Product Profiles and the regulatory package, built from your own data
- Freedom-to-operate (light), whitespace mapping, and diligence-ready data rooms
One engine behind both doors: a 25-year operator, an expert network on call, and AI agents against the published record -- days, not months, every claim traced to its source.
Who stands behind it
BigBio is Christopher Davis.
I have worked every gate the grid above names: bench discovery, diagnostics, a $1.2B commercial franchise, GxP manufacturing, and the investor table. "Point me at anything" is earned at each one, not asserted.
- NIBRR&D / HTS · 6M compounds screened
- MetamarkDiagnostics · ProMark, CLIA/CAP
- Shire$1.2B GI franchise · regulatory ops
- MangoFounder/CEO · zero to market: M6 90-min sterility test (vs 14-day standard), ~50 people, J&J partnership, revenue
- Private venture diligence50+ early-stage deals diligenced · confidential
Raised off-grid in a log cabin outside Anahim Lake, British Columbia -- no electricity, no running water -- now working at the bleeding edge of compute in Boston.
The full recordSee the work, then point me at yours.
Independent reads on the deal you’re weighing or the asset you’re building — every claim traced to its source, on a deadline.